All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Venetoclax Displays Durable Efficacy in Relapsed/Refractory CLL

March 14th 2024

Patients with relapsed/refractory chronic lymphocytic leukemia experienced long-lasting responses with venetoclax.

Multitargeted DNA Test Bests Fecal Immunochemical Test With Higher Sensitivity for CRC

March 13th 2024

Higher sensitivity for CRC and advanced precancerous lesions, but lower specificity for advanced neoplasia, was seen with a next-generation stool DNA test vs a fecal immunochemical test.

Perioperative Tislelizumab Shows Marked Benefit in Both Squamous and Nonsquamous Resectable NSCLC

March 13th 2024

Federico Cappuzzo, MD, discusses the clinical significance of the RATIONALE-315 trial of perioperative tislelizumab in non–small cell lung cancer.

First-Line Niraparib Maintenance Is Not Associated With Worse HRQOL in Advanced Ovarian Cancer

March 13th 2024

First-line niraparib maintenance was not associated with worsened health-related quality of life outcomes vs placebo in advanced ovarian cancer.

FDA Accepts NDA for Ensartinib in Metastatic ALK+ NSCLC

March 13th 2024

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

Patients With Cancer in Alabama 'Being Robbed of the Choice to Build a Family After Treatment'

March 13th 2024

A consequence of the Alabama Supreme Court’s in vitro fertilization ruling is an unacceptably high risk of infertility for patients with cancer.

FDA Grants Orphan Drug Designation to LYT-200 in AML

March 13th 2024

The FDA has granted orphan drug designation to LYT-200 for the treatment of acute myeloid leukemia.

Dual-Targeted CAR T-Cell Therapy Displays Early Efficacy in Recurrent Glioblastoma

March 13th 2024

A CAR T-cell therapy directed toward 2 brain tumor–associated proteins displayed preliminary activity in recurrent glioblastoma.

The Medical AI Revolution

March 13th 2024

We consider artificial intelligence hype vs reality, focusing on predictive modeling to answer medical questions about diagnosis, treatment choice, etc.

Heath Discusses Utility of NECTIN-4 as a Target in Urothelial Carcinoma

March 13th 2024

Elisabeth I. Heath, MD, FACP, discusses what makes NECTIN-4 an attractive target in drug development and the significance of the EV-302/KEYNOTE-A39 trial findings.

Analysis Shows Most EMA-Approved Oncology Drugs Recover R&D Costs, Irrespective of Added Benefit

March 12th 2024

Francine Brinkhuis, MSc, and Lourens T. Bloem, PharmD, MSc, highlight findings from an analysis of the benefit and revenue for EU-approved oncology drugs.

Emavusertib Progresses to Phase 2 Study in AML and MDS

March 12th 2024

The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.

Q-TWiST Analysis Demonstrates Benefit of Fruquintinib Plus BSC in Pretreated mCRC

March 12th 2024

Sebastien Stintzing, MD, discusses a Q-TWiST analysis for fruquintinib vs placebo in pretreated metastatic colorectal cancer.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

March 12th 2024

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

UChicago Medicine Among the First to Offer Histotripsy for Liver Tumors

March 12th 2024

The University of Chicago Medicine treats patients with histotripsy, a technology that uses ultrasound energy to destroy liver tumors.

TERN-701 Receives FDA Orphan Drug Designation in CML

March 12th 2024

TERN-701 has received orphan drug designation from the FDA for the treatment of patients with chronic myeloid leukemia.

Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL

March 12th 2024

Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.

APG-115 Produces Encouraging Disease Control in p53 Wild-Type Salivary Gland Cancer

March 12th 2024

A high rate of disease control was seen with the novel MDM2 inhibitor APG-115-alrizomadlin in patients with p53 wild-type salivary gland cancer.

Coming Full Circle

March 12th 2024

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

Modesitt Spotlights the Latest ADC Breakthroughs in Gynecologic Oncology

March 11th 2024

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.